Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN (ABC123)
Phase 1, Open-label Dose-escalation and Dose-expansion Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of a Single Dose of UCART123 (Allogeneic Engineered T-cells Expressing Anti-CD123 Chimeric Antigen Receptor), Administered in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Sponsor: Cellectis S.A.
Terminated
The trial was discontinued due to sponsor's decision and not a consequence of any safety concern.
Other terminated trials from Cellectis S.A.
More terminations from Cellectis S.A.
Listed as NCT03203369, this PHASE1 trial focuses on Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) and remains terminated or withdrawn. Sponsored by Cellectis S.A., it has been updated 10 times since 2017, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE1
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE1
▶ Show 5 earlier versions
-
Aug 2019 — Nov 2020 [monthly]
Terminated PHASE1
Status: Recruiting → Terminated
-
Jun 2018 — Aug 2019 [monthly]
Recruiting PHASE1
-
Jan 2018 — Jun 2018 [monthly]
Recruiting PHASE1
Status: Suspended → Recruiting
-
Oct 2017 — Jan 2018 [monthly]
Suspended PHASE1
Status: Recruiting → Suspended
-
Jul 2017 — Oct 2017 [monthly]
Recruiting PHASE1
First recorded
Jun 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cellectis S.A.
For direct contact, visit the study record on ClinicalTrials.gov .